WO2005094793A1 - Process for preparing a solid pharmaceutical composition - Google Patents

Process for preparing a solid pharmaceutical composition Download PDF

Info

Publication number
WO2005094793A1
WO2005094793A1 PCT/EP2005/003277 EP2005003277W WO2005094793A1 WO 2005094793 A1 WO2005094793 A1 WO 2005094793A1 EP 2005003277 W EP2005003277 W EP 2005003277W WO 2005094793 A1 WO2005094793 A1 WO 2005094793A1
Authority
WO
WIPO (PCT)
Prior art keywords
perindopril
process according
salt
carbonate
hydrate
Prior art date
Application number
PCT/EP2005/003277
Other languages
French (fr)
Inventor
Iztok Klobcar
Alesa Puncuh-Kolar
Anica Grandovec
Urska Turk
Polona Solmajer-Lampic
Original Assignee
Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005094793(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE200410019845 external-priority patent/DE102004019845A1/en
Priority claimed from DE102004059521A external-priority patent/DE102004059521A1/en
Application filed by Krka, Tovarna Zdravil, D.D., Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D., Novo Mesto
Priority to US10/599,154 priority Critical patent/US20070172524A1/en
Priority to LTEP05730288.7T priority patent/LT1729739T/en
Priority to ES05730288.7T priority patent/ES2603856T3/en
Priority to EP05730288.7A priority patent/EP1729739B1/en
Priority to JP2007505484A priority patent/JP4948392B2/en
Priority to DK05730288.7T priority patent/DK1729739T3/en
Priority to EA200601608A priority patent/EA011712B1/en
Publication of WO2005094793A1 publication Critical patent/WO2005094793A1/en
Priority to NO20064934A priority patent/NO20064934L/en
Priority to US12/477,727 priority patent/US20100172995A1/en
Priority to CY20161101118T priority patent/CY1118180T1/en
Priority to HRP20161602TT priority patent/HRP20161602T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof as well as a solid pharmaceutical composition.
  • ACE inhibitors such as Perindopril
  • Perindopril are a prodrug for perindo- prilat which is in vivo the actually active substance.
  • Especially solid formulations like tablets suffer from substantial degradation and thereby reduce the effective amount of perindopril.
  • the main degradation routes are 1) the hydrolysis of the ester group and 2) intramolecular cyclization resulting in diketopiperazine (DKP) , especially in an acidic environment .
  • DKP diketopiperazine
  • WO 03/075842 disclose formulations of moexipril hydro- chloride which have been stabilized by addition of alkali or alkaline earth metal carbonates.
  • a mixture including moexipril hydrochloride as well as the alkaline reacting carbonate is processed by wet granulation so that the stabilizing effect is likely due to the in-situ forming of the sodium salt of moexi- _ pril.
  • the_ amount_ of the carbonate should be greater than the stoichiometric amount of the moexipril hydrochloride.
  • US 5,350,582 discloses the use of stabilizing the ACE inhibitor enalapril maleate by addition of alkaline reacting substances which results in formation of the corresponding more stable sodium salt of enalapril.
  • This in- situ reaction may be accomplished by using sodium hydrogen carbonate and use of a wet granulation process which allows the neutralization between the alkaline stabilizer and the enalapril maleate to occur.
  • a wet granulation process which allows the neutralization between the alkaline stabilizer and the enalapril maleate to occur.
  • For 1 mole of enalapril maleate a total of 3 moles of sodium hydrogen carbonate are used.
  • the process according to the invention for preparing a solid pharmaceutical composition of perindopril or a salt thereof comprises
  • step (i) dry mixing of perindopril or a salt thereof with at least one inorganic carbonate, at least one carrier, and optionally other components, and (ii) dry processing of the mixture obtained in step (i) to the desired solid form.
  • perindopril or a salt thereof is dry mixed with at least one inorganic carbonate, at least one carrier and optionally other components.
  • dry mixing means that to none of the ingredients to be mixed a liquid, like water, ethanol or combinations thereof, is added and additionally that the mixing is effected without adding such a liquid.
  • perindopril is preferably used in form of its tert . -butylamine salt, which is also referred to as perindopril erbumine, as this leads to particularly stable compositions.
  • Perindopril erbumine can exist in various polymorphic forms, for example form ⁇ disclosed in WO 01/87835, form ⁇ disclosed in WO 01/87836 and form ⁇ disclosed in WO 01/83439. It is an advantage of the present commposition that an undesired transformation of a polymorph is prevented or at least strongly reduced.
  • the inorganic carbonate is preferably sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate, calcium hydrogen carbonate or a mixture thereof. It has further been shown that particularly stable compositions can be obtained when the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and more preferably 1 to 0.05-0.83.
  • the carrier can be an inorganic or organic substance.
  • Preferred examples of such carriers are dibasic calcium phosphate, triba- sic calcium phosphate, magnesium oxide, microcrystalline cellulose, powdered cellulose, lactose and starch.
  • the carrier is microcrystalline cellulose, lactose or a mixture thereof.
  • microcrystalline cellulose which has a low moisture content of 0.3 to 5.0 % by weight, preferably 0.3 to 1.5 % by weight.
  • the moisture content is determined as loss upon drying of a sample in a furnace at 100- 150°C until a constant mass is reached.
  • lactose is particularly preferably anhydrous lactose.
  • compositions which have been obtained by using microcrystalline cellulose of the afore-mentioned low moisture content and/or anhydrous lactose show a very low level of degradation and are therefore highly stable products.
  • lubricants may be selected from the group consisting of magnesium stearate, calcium stearate, castor oil, glycerol monostearate, hydrogenated vegetable oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
  • the composition also comprises indapamide or a hydrate thereof.
  • the water content of such a hydrate can vary depending on the humi- dity level of the atmosphere and can be up to 3 % in case of the hemihydrate .
  • a preferred hydrate is the hemihydrate .
  • compositions are preferred which comprise indapamide or a hydrate thereof in form of particles having specific sizes. It is preferred that 90 % by volume of the particles of indapamide or a hydrate thereof have a size of less than 80 ⁇ m, in particular of less than 70 ⁇ m.
  • step (ii) the obtained mixture is dry processed to the desired solid form.
  • dry processing means that no liquid is added to the mixture and that the processing is also effected without addition of any liquid. It is preferred that the mixture obtained in step (i) is processed by means of direct compression using a suitable apparatus, like a punch tableting machine.
  • the process according to the invention avoids the use of any liquids, including water or aqueous liquids, which on their own may lead to undesired degradation reactions . It is surprising that despite the avoiding of for example a wet granulation step it is possible by means of the process according to the invention to produce very stable compositions of perindopril or a salt thereof. In particular, it was found that tablets prepared according to the present process, after storage, form only small amounts of diketopiperazine (DKP) . It is furthermore surprising that the use of small amounts of inorganic carbonate, i.e. below the stoichiometric amount, provide an additional stabilizing effect even though according to the prior art at least stoichiometric amounts need to be used.
  • DKP diketopiperazine
  • the process according to the invention preferably results in tablets, minitablets or granules.
  • the invention also relates to a solid pharmaceutical composition of perindopril or salt thereof, comprising
  • perindopril or a salt thereof at least one of microcrystalline cellulose having a moisture content of 0.3 to 5.0 % by weight and anhydrous lactose, (c) optionally at least one inorganic carbonate, and (d) optionally other components.
  • the preferred embodiments of these composition have already been described above with respect to the process according to the invention.
  • at least one inorganic carbonate is present in the composition according to the invention.
  • the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50-0.83.
  • composition further comprises indapamide or a hydrate thereof. It is also preferred that 90 % by volume of the particles of indapamide or a hydrate thereof have a size of less than 80 ⁇ m, in particular of less than 70 ⁇ m.
  • microcrystalline cellulose preferably has a moisture content of 0.3 to 1.5 % weight.
  • the present process does not lead to a substantial transformation of polymorphs of perindopril or a salt thereof which is a further benefit in relation to conventional processes.
  • Example 1 (comparison) and Examples 2 to 7 (invention)
  • lactose anhydrous is lactose having a water content of less than 1% by weight, determined by Karl-Fischer method according to Ph.Eur. 2.5.12.
  • the tablets prepared according to example 1 and according to examples 2, 3 and 4 were stored for 3 weeks at 50°C in closed containers.
  • the results given below show the amount of diketopiperazine after 3 weeks .
  • example 1 shows that even without alkaline reacting carbonate there is a decrease of the quantity of diketopiperazine in case of example 4 using micro- crystalline cellulose of a low moisture content.
  • examples 2 and 3 even more decreased amounts of diketopiperazine were determined and these examples include as a stabilizer sodium hydrogen carbonate.
  • the amount of diketopiperazine was determined with a HPLC method using a Hypersil ODS column, 250mm x 4.6mm i.d., packed with 5 ⁇ m particles, and a detector operating at a wavelength of 215mm.
  • a gradient elution was effected using the following mobile phase A: buffer solution of pH 2.0 prepared by adding into a 1000ml volumetric flask, 0.92g sodium heptansulfonate, and 1ml Triethylamin (TEA) and filling with water to volume, and adjusting pH value of solution to 2.0 with perchloric acid B: acetonitrile
  • the flow rate of the mobile phase was set to 1.0 ml/min and the column temperature was set at 70 °C. 20 ⁇ l of a standard solution and of the sample solution at a working concentration of about 3.0 mg/ml of perindopril erbumine in the buffer solution of pH 2.0 were injected. Diketopiperazine was detected on basis the of the retention time of the DKP peak on the chromatogram of the standard solution. The percentage of diketopiperazine was calculated as area %.
  • Tablets according to examples 2, 3 and 4 were additionally stored for 4 weeks at 40 °C in 75% relative humidity in closed containers. Again, the amounts of the degradation product diketopiperazine were determined as mentioned above and the results are given in the table below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compositions, like tablets.

Description

Process for preparing a solid pharmaceutical composition
The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof as well as a solid pharmaceutical composition.
ACE inhibitors, such as Perindopril, are a prodrug for perindo- prilat which is in vivo the actually active substance. Especially solid formulations like tablets suffer from substantial degradation and thereby reduce the effective amount of perindopril. The main degradation routes are 1) the hydrolysis of the ester group and 2) intramolecular cyclization resulting in diketopiperazine (DKP) , especially in an acidic environment .
There have been various attempts to stabilize solid compositions of ACE inhibitors. According to EP-280 999 alkali or alkaline earth metal carbonates have been used to stabilize ACE inhibitor formulations. It is disclosed that in particular magnesium carbonate is a suit- able stabilizing carbonate which proves to be effective when combined with enalpril. The components of the compositions are processed by means of wet granulation to the desired tablets.
Further WO 03/075842 disclose formulations of moexipril hydro- chloride which have been stabilized by addition of alkali or alkaline earth metal carbonates. A mixture including moexipril hydrochloride as well as the alkaline reacting carbonate is processed by wet granulation so that the stabilizing effect is likely due to the in-situ forming of the sodium salt of moexi- _ pril. It is further disclosed that the_ amount_ of the carbonate should be greater than the stoichiometric amount of the moexipril hydrochloride.
In the same manner US 5,350,582 discloses the use of stabilizing the ACE inhibitor enalapril maleate by addition of alkaline reacting substances which results in formation of the corresponding more stable sodium salt of enalapril. This in- situ reaction may be accomplished by using sodium hydrogen carbonate and use of a wet granulation process which allows the neutralization between the alkaline stabilizer and the enalapril maleate to occur. For 1 mole of enalapril maleate a total of 3 moles of sodium hydrogen carbonate are used.
However, the afore-mentioned approaches of obtaining stabilized formulations of ACE inhibitors, like perindopril, suffer from the drawback that they always include use of water which in turn can give rise to a reduced stability. Moreover, these processes often do not allow to prepare a pharmaceutical composition which shows a satisfactory level of stability, especially when stored over long periods of time. Finally, the use of a wet granulation step always requires means to remove the granulation liquid at a later stage in order to arrive at the final solid composition.
It is therefore an object of the present invention to provide a process for preparing a solid pharmaceutical composition of perindopril which avoids the above problems of the conventional processes as well as a solid pharmaceutical composition of perindopril which has a high stability and contains only minor amounts of degradation products .
This object is surprisingly achieved by the process according to claims 1 to 12 and the composition according to claims 13 to 17.
The process according to the invention for preparing a solid pharmaceutical composition of perindopril or a salt thereof comprises
(i) dry mixing of perindopril or a salt thereof with at least one inorganic carbonate, at least one carrier, and optionally other components, and (ii) dry processing of the mixture obtained in step (i) to the desired solid form.
In step (i) perindopril or a salt thereof is dry mixed with at least one inorganic carbonate, at least one carrier and optionally other components. The term "dry mixing" means that to none of the ingredients to be mixed a liquid, like water, ethanol or combinations thereof, is added and additionally that the mixing is effected without adding such a liquid.
Investigations have shown that the perindopril is preferably used in form of its tert . -butylamine salt, which is also referred to as perindopril erbumine, as this leads to particularly stable compositions.
Perindopril erbumine can exist in various polymorphic forms, for example form α disclosed in WO 01/87835, form β disclosed in WO 01/87836 and form γ disclosed in WO 01/83439. It is an advantage of the present commposition that an undesired transformation of a polymorph is prevented or at least strongly reduced.
The inorganic carbonate is preferably sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate, calcium hydrogen carbonate or a mixture thereof. It has further been shown that particularly stable compositions can be obtained when the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and more preferably 1 to 0.05-0.83.
The carrier can be an inorganic or organic substance. Preferred examples of such carriers are dibasic calcium phosphate, triba- sic calcium phosphate, magnesium oxide, microcrystalline cellulose, powdered cellulose, lactose and starch. In a more preferred embodiment the carrier is microcrystalline cellulose, lactose or a mixture thereof.
Particularly preferred is a microcrystalline cellulose which has a low moisture content of 0.3 to 5.0 % by weight, preferably 0.3 to 1.5 % by weight. The moisture content is determined as loss upon drying of a sample in a furnace at 100- 150°C until a constant mass is reached.
Additionally, the lactose is particularly preferably anhydrous lactose.
Compositions which have been obtained by using microcrystalline cellulose of the afore-mentioned low moisture content and/or anhydrous lactose show a very low level of degradation and are therefore highly stable products.
Optionally present other components are those conventionally used in the manufacture of pharmaceutical compositions and in- elude for example disintegrants and lubricants. Preferred lubricants may be selected from the group consisting of magnesium stearate, calcium stearate, castor oil, glycerol monostearate, hydrogenated vegetable oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
It has further been found particularly preferred that the composition also comprises indapamide or a hydrate thereof. The water content of such a hydrate can vary depending on the humi- dity level of the atmosphere and can be up to 3 % in case of the hemihydrate . A preferred hydrate is the hemihydrate .
It has also been shown that compositions are preferred which comprise indapamide or a hydrate thereof in form of particles having specific sizes. It is preferred that 90 % by volume of the particles of indapamide or a hydrate thereof have a size of less than 80μm, in particular of less than 70μm.
These preferred particle sizes have a beneficial influence on content uniformity and the release profile of the composition.
In step (ii) the obtained mixture is dry processed to the desired solid form. The term "dry processing" means that no liquid is added to the mixture and that the processing is also effected without addition of any liquid. It is preferred that the mixture obtained in step (i) is processed by means of direct compression using a suitable apparatus, like a punch tableting machine.
Thus, the process according to the invention avoids the use of any liquids, including water or aqueous liquids, which on their own may lead to undesired degradation reactions . It is surprising that despite the avoiding of for example a wet granulation step it is possible by means of the process according to the invention to produce very stable compositions of perindopril or a salt thereof. In particular, it was found that tablets prepared according to the present process, after storage, form only small amounts of diketopiperazine (DKP) . It is furthermore surprising that the use of small amounts of inorganic carbonate, i.e. below the stoichiometric amount, provide an additional stabilizing effect even though according to the prior art at least stoichiometric amounts need to be used.
The process according to the invention preferably results in tablets, minitablets or granules. Further, the invention also relates to a solid pharmaceutical composition of perindopril or salt thereof, comprising
(a) perindopril or a salt thereof, (b) at least one of microcrystalline cellulose having a moisture content of 0.3 to 5.0 % by weight and anhydrous lactose, (c) optionally at least one inorganic carbonate, and (d) optionally other components.
The preferred embodiments of these composition have already been described above with respect to the process according to the invention. In such a preferred embodiment at least one inorganic carbonate is present in the composition according to the invention. In particular, it is preferred that the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50-0.83.
It is also preferred that the composition further comprises indapamide or a hydrate thereof. It is also preferred that 90 % by volume of the particles of indapamide or a hydrate thereof have a size of less than 80μm, in particular of less than 70μm.
Moreover, the microcrystalline cellulose preferably has a moisture content of 0.3 to 1.5 % weight.
It has surprisingly been shown that by using perindopril or a salt thereof in combination with either microcrystalline cellu- lose having the specified moisture content of 0.3 to 5.0 % weight and/or anhydrous lactose a very stable composition is obtained. This is in contrast to the teaching of the prior art where the presence of liquid, such as water, is generally required for a wet granulation step or a neutralization reaction between alkaline stabilizer and acidic ACE inhibitor.
Additionally, the present process does not lead to a substantial transformation of polymorphs of perindopril or a salt thereof which is a further benefit in relation to conventional processes.
The following examples serve to illustrate the invention in more detail.
Examples
Example 1 (comparison) and Examples 2 to 7 (invention)
For the examples 2 to 4 (invention) perindopril erbumine as well as the materials used as carriers as well as the other components were screened. In examples 5 to 7 the preferred combination of perindopril erbumine with indapamide was used. The screened materials with the exception of the lubricant magnesium stearate were dry blended. Subsequently, the magnesium stearate was added to the resulting mixture and the mixture was homogenized. The homogenized mixture was then compressed using a punch tableting machine, Exacta X of Wilhelm Fette, to give tablets. As a comparison currently marketed tablets containing perindopril erbumine were used having the composition as given in the table below for example 1. Table 1
Figure imgf000009_0003
Figure imgf000009_0001
* lactose anhydrous is lactose having a water content of less than 1% by weight, determined by
Figure imgf000009_0002
Karl-Fischer method according to Ph.Eur. 2.5.12.
The tablets prepared according to example 1 and according to examples 2, 3 and 4 were stored for 3 weeks at 50°C in closed containers. The results given below show the amount of diketopiperazine after 3 weeks .
Figure imgf000010_0001
The comparison of example 1 with example 4 shows that even without alkaline reacting carbonate there is a decrease of the quantity of diketopiperazine in case of example 4 using micro- crystalline cellulose of a low moisture content. In case of examples 2 and 3 even more decreased amounts of diketopiperazine were determined and these examples include as a stabilizer sodium hydrogen carbonate.
The amount of diketopiperazine was determined with a HPLC method using a Hypersil ODS column, 250mm x 4.6mm i.d., packed with 5μm particles, and a detector operating at a wavelength of 215mm.
A gradient elution was effected using the following mobile phase A: buffer solution of pH 2.0 prepared by adding into a 1000ml volumetric flask, 0.92g sodium heptansulfonate, and 1ml Triethylamin (TEA) and filling with water to volume, and adjusting pH value of solution to 2.0 with perchloric acid B: acetonitrile
Figure imgf000011_0001
The flow rate of the mobile phase was set to 1.0 ml/min and the column temperature was set at 70 °C. 20μl of a standard solution and of the sample solution at a working concentration of about 3.0 mg/ml of perindopril erbumine in the buffer solution of pH 2.0 were injected. Diketopiperazine was detected on basis the of the retention time of the DKP peak on the chromatogram of the standard solution. The percentage of diketopiperazine was calculated as area %.
Tablets according to examples 2, 3 and 4 were additionally stored for 4 weeks at 40 °C in 75% relative humidity in closed containers. Again, the amounts of the degradation product diketopiperazine were determined as mentioned above and the results are given in the table below.
Figure imgf000011_0002
These experiments showed that a particularly stable composition was obtained in case of examples 2 and 3 which have been prepared without using any wet granulation step and which include sodium hydrogen carbonate as a stabilizer.
Thus, the above experiments show that by suitable selection of excipients and the avoiding of a wet granulation step tablets can be obtained which are, even in the presence of moisture, very stable against degradation.

Claims

Claims
1. Process for preparing a solid pharmaceutical composition of perindopril or a salt thereof, comprising
(i) dry mixing of perindopril or a salt thereof with at least one inorganic carbonate, at least one carrier, and optionally other components, and (ii) dry processing of the mixture obtained in step (i) to the desired solid form.
2. Process according to claim 1, wherein the composition comprises the tert. -butyl amine salt of perindopril.
3. Process according to claim 1 or 2, wherein the inorganic carbonate is sodium carbonate, sodium hydrogen carbonate, magnesium carbonate, calcium carbonate or calcium hydrogen carbonate.
4. Process according to any one of claims 1 to 3, wherein the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50-0.83.
5. Process according to any one of claims 1 to 4 , wherein the carrier is microcrystalline cellulose, lactose or a mixture thereof.
6. Process according to claim 5, wherein the microcrystalline cellulose has a moisture content of 0.3 to 5.0 % by weight, preferably 0.3 to 1.5 % by weight .
7. Process according to claim 5 or 6, wherein the lactose is anhydrous lactose.
8. Process according to any one of claims 1 to 7, wherein step (ii) is effected by direct compression of the mixture .
9. Process according to any one of claims 1 to 8, wherein the composition also comprises indapamide or a hydrate thereof.
10. Process according to claim 9, wherein the hydrate is indapamide hemihydrate .
11. Process according to claim 9 or 10, wherein 90 % of the particles of indapamide or a hydrate thereof have a size of less than 80μm.
12. Process according to claim 11, wherein 90 % of the particles of indapamide or a hydrate thereof have a size of less than 70μm.
13. Solid pharmaceutical composition of perindopril or a salt thereof, comprising
(a) perindopril or a salt thereof, (b) at least one of microcrystalline cellulose hav¬ ing amoisture content of 0.3 to 5.0 % by weight and anhydrous lactose, (c) optionally at least one inorganic carbonate, and (d) optionally other components.
14. Composition according to claim 13, wherein the molar ratio of perindopril or a salt thereof to inorganic carbonate is 1 to 0.1-0.9 and preferably 1 to 0.50- 0.83.
15. Composition according to claim 13 or 14, wherein the microcrystalline cellulose has a moisture content of
0 . 3 to 1 . 5 % by weight .
16. Composition according to claim 15 which further comprises indapamide or a hydrate thereof.
17. Composition according to claim 16, wherein 90 % by volume of the particles of indapamide or a hydrate thereof have a size of less than 80μm.
PCT/EP2005/003277 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition WO2005094793A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US10/599,154 US20070172524A1 (en) 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition
LTEP05730288.7T LT1729739T (en) 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition
ES05730288.7T ES2603856T3 (en) 2004-03-29 2005-03-29 Procedure for preparing a solid pharmaceutical composition
EP05730288.7A EP1729739B1 (en) 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition
JP2007505484A JP4948392B2 (en) 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition
DK05730288.7T DK1729739T3 (en) 2004-03-29 2005-03-29 PROCESS FOR THE PREPARATION OF A solid pharmaceutical composition.
EA200601608A EA011712B1 (en) 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition
NO20064934A NO20064934L (en) 2004-03-29 2006-10-27 Process for the preparation of a solid pharmaceutical composition
US12/477,727 US20100172995A1 (en) 2004-03-29 2009-06-03 Process For Preparing A Solid Pharmaceutical Composition
CY20161101118T CY1118180T1 (en) 2004-03-29 2016-11-03 METHOD FOR PRODUCTION OF SOLID PHARMACEUTICAL COMPOSITION
HRP20161602TT HRP20161602T1 (en) 2004-03-29 2016-11-30 Process for preparing a solid pharmaceutical composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE200410019845 DE102004019845A1 (en) 2004-03-29 2004-03-29 Solid composition used as acetyl cholinesterase inhibitor comprises perindopril, microcrystalline cellulose, inorganic carbonate and other components
DE102004019845.4 2004-03-29
DE102004059521.6 2004-12-09
DE102004059521A DE102004059521A1 (en) 2004-12-09 2004-12-09 Solid composition used as acetyl cholinesterase inhibitor comprises perindopril, microcrystalline cellulose, inorganic carbonate and other components

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/477,727 Division US20100172995A1 (en) 2004-03-29 2009-06-03 Process For Preparing A Solid Pharmaceutical Composition

Publications (1)

Publication Number Publication Date
WO2005094793A1 true WO2005094793A1 (en) 2005-10-13

Family

ID=34963866

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/003277 WO2005094793A1 (en) 2004-03-29 2005-03-29 Process for preparing a solid pharmaceutical composition

Country Status (14)

Country Link
US (2) US20070172524A1 (en)
EP (1) EP1729739B1 (en)
JP (1) JP4948392B2 (en)
CY (1) CY1118180T1 (en)
DK (1) DK1729739T3 (en)
EA (1) EA011712B1 (en)
ES (1) ES2603856T3 (en)
HR (1) HRP20161602T1 (en)
HU (1) HUE031058T2 (en)
LT (1) LT1729739T (en)
NO (1) NO20064934L (en)
PL (1) PL1729739T3 (en)
PT (1) PT1729739T (en)
WO (1) WO2005094793A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025695A1 (en) * 2005-08-30 2007-03-08 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising perindopril or its salts
WO2007058634A1 (en) * 2005-11-17 2007-05-24 Diagen Smartno Pri Ljubljani, D.O.O. Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
WO2007120930A2 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
WO2008068577A2 (en) * 2006-12-01 2008-06-12 Glenmark Pharmaceuticals Limited Pharmaceutical compositions
JP2009537538A (en) * 2006-05-15 2009-10-29 アカドイア プハルマセウチカルス インコーポレーテッド Pimavanserin pharmaceutical formulation
JP2010516699A (en) * 2007-01-18 2010-05-20 エヴォルヴァ エスアー Substituted 1,3-dioxanes useful as PPAR modulators
US8470869B2 (en) 2007-06-27 2013-06-25 Krka, Tovarna Zdravil D.D. Novo Mesto Salts of perindopril
WO2014076632A1 (en) 2012-11-15 2014-05-22 Adamed Sp. Z O.O. A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
EP1729739B1 (en) 2004-03-29 2016-09-28 Les Laboratoires Servier Process for preparing a solid pharmaceutical composition
CN109700774A (en) * 2019-03-05 2019-05-03 上药东英（江苏）药业有限公司 A kind of perindopril tert-butylamine piece and its powder vertical compression technique

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21800A (en) * 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril
TWI435917B (en) 2006-12-27 2014-05-01 Fujifilm Corp Pigment-dispersed composition, curable composition, color filter and production method thereof
WO2011087629A2 (en) * 2009-12-22 2011-07-21 Fmc Corporation Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011709A2 (en) 2000-08-05 2002-02-14 Hexal Ag Pharmaceutical, effervescent formulation containing ramipril
EP1203580A1 (en) 1999-06-18 2002-05-08 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US20020119192A1 (en) 2000-09-22 2002-08-29 Vishwanathan Narayanan Badri Controlled release formulations for oral administration
WO2003028707A1 (en) 2001-09-28 2003-04-10 Bernard Charles Sherman Solid compositions comprising ramipril
WO2003059388A1 (en) * 2002-01-15 2003-07-24 Delta Hf. Formulations of quinapril and related ace inhibitors
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
WO2005011737A2 (en) * 2003-07-30 2005-02-10 Cipla Limited Pharmaceutical combinations and formulations with improved stability

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4350704A (en) * 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
FR2620699B1 (en) * 1987-09-17 1990-06-01 Adir PROCESS FOR THE SYNTHESIS OF ALPHA AMINO N ALKYL ACIDS AND THEIR ESTERS. APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES
FR2620709B1 (en) * 1987-09-17 1990-09-07 Adir PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERINDOPRIL AND ITS MAIN INTERMEDIATE SYNTHESIS
FR2620703B1 (en) * 1987-09-17 1991-10-04 Adir PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERHYDROINDOLE CARBOXYLIC ACID - 2 (2S, 3AS, 7AS). APPLICATION TO THE SYNTHESIS OF CARBOXYALKYL DIPEPTIDES
US5258525A (en) * 1991-03-27 1993-11-02 Mcneilab, Inc. Processes for preparing [2S-(2α,3aβ,7aβ)]octahydro-1H-indole-2-carboxylic acid and esters
YU48602B (en) * 1991-11-25 1998-12-23 Krka Tovarna Zdravil P.O. Procedure for obtaining stable formulation of the enalaprile salts
FR2771010B1 (en) * 1997-11-19 2003-08-15 Adir USE OF A COMBINATION OF AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR AND A DIURETIC FOR THE TREATMENT OF MICROCIRCULATORY DISORDERS
FR2807037B1 (en) * 2000-03-31 2002-05-10 Adir NOVEL PROCESS FOR SYNTHESIS OF N - [(s) -1- CARBOXYBUTYL] - (S) -ALANINE ESTERS AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL
FR2807431B1 (en) * 2000-04-06 2002-07-19 Adir NOVEL PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
FR2807430B1 (en) * 2000-04-11 2002-05-17 Adir NOVEL PROCESS FOR THE SYNTHESIS OF N - [(S) -1- CARBOXYBUTYL] - (S) -ALANINE ESTERS AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL
FR2811318B1 (en) * 2000-07-06 2002-08-23 Adir NOVEL GAMMA CRYSTALLINE FORM OF TERT-BUTYLAMINE SALT OF PERINDOPRIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2811319B1 (en) 2000-07-06 2002-08-23 Adir NOVEL BETA CRYSTALLINE FORM OF TERT-BUTYLAMINE SALT OF PERINDOPRIL, ITS PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2811320B1 (en) * 2000-07-06 2002-08-23 Adir NOVEL ALPHA CRYSTALLINE FORM OF TERT-BUTYLAMINE SALT OF PERINDOPRIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
DE10131217A1 (en) * 2001-06-28 2003-01-09 Solvay Pharm Gmbh 3-phenyl-3,7-diazabicyclo 3,3,1 nonane compounds and processes for their preparation and medicaments containing these compounds
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CA2463495C (en) * 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
WO2003043603A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
EP1333026B1 (en) * 2002-01-30 2007-06-27 Les Laboratoires Servier Process for the preparation of high purity perindopril and intermediates useful in the synthesis
WO2003075842A2 (en) * 2002-03-08 2003-09-18 Teva Pharmeceuticals Usa, Inc. Stable formulations of angiotensin converting enzyme (ace) inhibitors
FR2838648B1 (en) 2002-04-18 2004-05-21 Servier Lab NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
US7763278B2 (en) * 2002-06-10 2010-07-27 Elan Pharma International Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
GB0301471D0 (en) 2003-01-22 2003-02-19 Biochemie Gmbh Organic compounds
ATE395913T1 (en) * 2003-02-28 2008-06-15 Servier S A Lab METHOD FOR PRODUCING PERINDOPRIL
ES2250847T3 (en) * 2003-02-28 2006-04-16 Les Laboratoires Servier NEW ACID SYNTHESIS PROCEDURE (2S, 3AS, 7AS) -PERHYDROINDOL-2-CARBOXYL AND ITS ETERES AND ITS APPLICATION TO PERINDROPIL SYNTHESIS.
DK1635792T3 (en) * 2003-06-26 2009-06-15 Teva Pharma Stable pharmaceutical compositions of 2-aza-bicyclo-3.3.0-octane-3-carboxylic acid derivatives
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
ATE445588T1 (en) * 2003-09-01 2009-10-15 Servier Lab NEW PROCESS FOR PRODUCING ESTERS OF N-((S)-1-CARBOXYBUTYL)-(S)-ALANINE AND ITS USE IN THE SYNTHESIS OF PERINDOPRIL
PL1729739T3 (en) 2004-03-29 2017-04-28 Les Laboratoires Servier Process for preparing a solid pharmaceutical composition
SI21800A (en) * 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1203580A1 (en) 1999-06-18 2002-05-08 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
WO2002011709A2 (en) 2000-08-05 2002-02-14 Hexal Ag Pharmaceutical, effervescent formulation containing ramipril
US20020119192A1 (en) 2000-09-22 2002-08-29 Vishwanathan Narayanan Badri Controlled release formulations for oral administration
WO2003028707A1 (en) 2001-09-28 2003-04-10 Bernard Charles Sherman Solid compositions comprising ramipril
WO2003059388A1 (en) * 2002-01-15 2003-07-24 Delta Hf. Formulations of quinapril and related ace inhibitors
WO2005011737A2 (en) * 2003-07-30 2005-02-10 Cipla Limited Pharmaceutical combinations and formulations with improved stability
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1729739B1 (en) 2004-03-29 2016-09-28 Les Laboratoires Servier Process for preparing a solid pharmaceutical composition
WO2007025695A1 (en) * 2005-08-30 2007-03-08 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising perindopril or its salts
EP1948224A1 (en) 2005-11-17 2008-07-30 Diagen Smartno pri Ljubljani, d.o.o. Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
WO2007058634A1 (en) * 2005-11-17 2007-05-24 Diagen Smartno Pri Ljubljani, D.O.O. Stable formulation of amorphous perindopril salts, a process for their preparation, especially industrial preparation, and their use in the therapy of hypertension
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
WO2007120930A2 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
JP2009533461A (en) * 2006-04-19 2009-09-17 テバ ファーマシューティカル インダストリーズ リミティド Stable pharmaceutical composition of 2-aza-bicyclo [3.3.0] -octane-3-carboxylic acid derivative
WO2007120930A3 (en) * 2006-04-19 2008-02-07 Teva Pharma Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
JP2009537538A (en) * 2006-05-15 2009-10-29 アカドイア プハルマセウチカルス インコーポレーテッド Pimavanserin pharmaceutical formulation
WO2008068577A2 (en) * 2006-12-01 2008-06-12 Glenmark Pharmaceuticals Limited Pharmaceutical compositions
WO2008068577A3 (en) * 2006-12-01 2009-04-23 Glenmark Pharmaceuticals Ltd Pharmaceutical compositions
JP2010516699A (en) * 2007-01-18 2010-05-20 エヴォルヴァ エスアー Substituted 1,3-dioxanes useful as PPAR modulators
US8470869B2 (en) 2007-06-27 2013-06-25 Krka, Tovarna Zdravil D.D. Novo Mesto Salts of perindopril
WO2014076632A1 (en) 2012-11-15 2014-05-22 Adamed Sp. Z O.O. A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
CN109700774A (en) * 2019-03-05 2019-05-03 上药东英（江苏）药业有限公司 A kind of perindopril tert-butylamine piece and its powder vertical compression technique

Also Published As

Publication number Publication date
LT1729739T (en) 2016-11-10
JP2007530623A (en) 2007-11-01
ES2603856T3 (en) 2017-03-01
PL1729739T3 (en) 2017-04-28
EA200601608A1 (en) 2007-02-27
US20070172524A1 (en) 2007-07-26
JP4948392B2 (en) 2012-06-06
EA011712B1 (en) 2009-04-28
HRP20161602T1 (en) 2016-12-30
NO20064934L (en) 2006-10-27
EP1729739B1 (en) 2016-09-28
DK1729739T3 (en) 2016-10-31
CY1118180T1 (en) 2017-06-28
EP1729739A1 (en) 2006-12-13
PT1729739T (en) 2016-12-01
US20100172995A1 (en) 2010-07-08
HUE031058T2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
EP1729739B1 (en) Process for preparing a solid pharmaceutical composition
EA015682B1 (en) Pharmaceutical composition
US4666919A (en) Stabilized pharmaceutical composition containing an isocarbostyril derivative
EP1721610B1 (en) Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
US10188737B2 (en) Stabilized pharmaceutical composition
EP1736156A1 (en) STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1|OCT-3-YL|-2-¬1-METHYLBUT-2-YNYLOXY|-BENZAMIDE CONTAINING COMPOSITION
WO2008132756A1 (en) Stable pharmaceutical compositions of ramipril
US7807196B2 (en) Process for drying amoxicillin
KR20110092804A (en) Pharmaceutical composition containing pitavastatin calcium salt
JP5113476B2 (en) Temocapril hydrochloride tablets with excellent storage stability
JP5809467B2 (en) Pitavastatin-containing composition and method for producing the same
AU701154B2 (en) Pyrrolidinyl methyl indole salt
UA86969C2 (en) Process for preparing a solid pharmaceutical composition
WO2003097039A1 (en) Stable dosage forms comprising atorvastatin calcium
JPWO2004047822A1 (en) Hydroxypropyl methylcellulose capsule formulation filled with teprenone
WO2006123358A2 (en) Stabilized atorvastatin-containing formulation
JP2004250382A (en) Package of solid preparation containing pravastatin sodium
JP2000219639A (en) Pharmaceutical composition
JP2003095939A (en) Stable pravastatin sodium tablet
WO2008133537A1 (en) Pharmaceutical composition exhibiting improved stability comprising ace inhibitor or pharmaceutically acceptable salt thereof and method for manufacturing thereof
CA2831340A1 (en) Excipient compatibility with ezatiostat
WO2008152598A1 (en) Stabilized pharmaceutical compositions comprising atorvastatin
JP2004250398A (en) Pharmaceutical composition comprising stabilized enalapril maleate
MXPA01005747A (en) Pharmaceutical compositions comprising quinapril magnesium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007505484

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200601608

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

REEP Request for entry into the european phase

Ref document number: 2005730288

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005730288

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005730288

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007172524

Country of ref document: US

Ref document number: 10599154

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10599154

Country of ref document: US